Kevin Joseph Fitzgerald Sells 2,441 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

Key Points

• Kevin Joseph Fitzgerald, EVP of Alnylam Pharmaceuticals, sold 2,441 shares of the company's stock for a total of $1,103,454.05, reducing his ownership by 8.82% to 25,231 shares.
• Alnylam Pharmaceuticals reported a positive earnings per share (EPS) of $0.32 for the last quarter, exceeding analysts' expectations, with revenues of $773.69 million, a 17.3% year-over-year increase.
• Institutional investors currently hold 92.97% of Alnylam's stock, indicating strong confidence from large financial entities in the company's performance and stability.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) EVP Kevin Joseph Fitzgerald sold 2,441 shares of the company's stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total value of $1,103,454.05. Following the completion of the sale, the executive vice president directly owned 25,231 shares of the company's stock, valued at approximately $11,405,673.55. This represents a 8.82% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Kevin Joseph Fitzgerald also recently made the following trade(s):

• On Monday, August 18th, Kevin Joseph Fitzgerald sold 1,396 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $453.27, for a total value of $632,764.92.

Alnylam Pharmaceuticals Price Performance

ALNY traded down $4.64 during midday trading on Friday, hitting $456.35. The stock had a trading volume of 969,084 shares, compared to its average volume of 982,632. The company has a market cap of $59.82 billion, a P/E ratio of -184.76 and a beta of 0.36. The business has a fifty day moving average of $439.02 and a 200 day moving average of $337.29. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $484.21.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.86. The business had revenue of $773.69 million during the quarter, compared to analyst estimates of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.Alnylam Pharmaceuticals's revenue for the quarter was up 17.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.13) earnings per share. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. SVB Wealth LLC bought a new position in shares of Alnylam Pharmaceuticals during the first quarter valued at $27,000. Whipplewood Advisors LLC increased its holdings in shares of Alnylam Pharmaceuticals by 208.8% during the first quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 71 shares in the last quarter. Bessemer Group Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 176.9% during the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock valued at $29,000 after acquiring an additional 69 shares in the last quarter. Atlantic Union Bankshares Corp bought a new position in shares of Alnylam Pharmaceuticals during the second quarter valued at $30,000. Finally, Elevation Point Wealth Partners LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the second quarter valued at $37,000. 92.97% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on ALNY. Truist Financial began coverage on Alnylam Pharmaceuticals in a research note on Monday, July 21st. They set a "buy" rating and a $385.00 price objective for the company. Bank of America increased their price objective on Alnylam Pharmaceuticals from $453.00 to $520.00 and gave the company a "buy" rating in a research note on Wednesday, September 17th. Jefferies Financial Group increased their price objective on Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the company a "buy" rating in a research note on Monday, July 7th. Barclays lifted their price target on shares of Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the company an "overweight" rating in a report on Friday, August 1st. Finally, Piper Sandler upped their price objective on shares of Alnylam Pharmaceuticals from $304.00 to $449.00 and gave the stock an "overweight" rating in a report on Friday, August 1st. Twenty-four investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $439.58.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.